88269-39-0

Basic information

• Product Name: (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid
• Synonyms: (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid;Inositol 1,4,5-trisphosphate;1D-Myo-inositol 1,4,5-trisphosphate;C01245
• CAS NO: 88269-39-0
• Molecular Formula: C₆H₁₅O₁₅P₃
• Molecular Weight: 420.1
• Mol File: 88269-39-0.mol
• Article Data: 36

Chemical Properties

• Boiling Point: 877.576°C at 760 mmHg
• Flash Point: 484.541°C
• Appearance: /
• Density: 2.25g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.636
• PKA: 1.91±0.10(Predicted)
• CAS DataBase Reference: (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid(88269-39-0)
• EPA Substance Registry System: (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid(88269-39-0)

Safety Data

• Hazardous Substances Data: 88269-39-0(Hazardous Substances Data)

Usage

Description

(2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid, also known as etidronic acid, is a synthetic organic compound belonging to the bisphosphonate family. It features a cyclohexane ring with hydroxyl and phosphonate groups, which provide strong chelating properties. This allows the compound to bind to calcium ions in bones, making it a potential candidate for medical and industrial applications.
Used in Pharmaceutical Industry:
(2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid is used as a medication for treating osteoporosis and other bone diseases. Its ability to bind to calcium ions in bones helps inhibit bone resorption and promote bone mineralization, making it an effective treatment for conditions characterized by bone loss.
Used in Industrial Applications:
(2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid is used as a chelating agent in the production of detergents and water treatment processes. Its strong chelating properties enable it to bind to metal ions, improving the efficiency of these products.
Safety Precautions:
It is important to handle (2,3,6-trihydroxy-4,5-diphosphonooxy-cyclohexoxy)phosphonic acid with care, as it can be harmful if ingested or inhaled and can cause skin and eye irritation. Proper safety measures should be taken during its production, use, and disposal to minimize potential health risks.

InChI:InChI=1/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1

Upstream product

• 141611-64-5 1L-1,2,4-tri-O-benzyl-3,5,6-tris-O-(o-xylylenedioxyphosphoryl)-myo-inositol 
• 119525-96-1 D-6-O-<2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl>-2,3-O-isopropylidene-myo-inositol 1,4,5-tris(dibenzylphosphate) 
• 108268-52-6 (D)-4-O-benzyl-2,3-O-cyclohexylidene-myo-inositol 1,4,5-(hexabenzyl)trisphosphate 
• 116907-55-2 1L-1,2,4-tri-O-benzyl-3,5,6-tris-O-dibenzyloxyphosphoryl-myo-inositol 
• 138480-23-6 D-6-O-benzyl-2,3-O-(D-1,7,7-trimethyl<2.2.1>bicyclohept-2-ylidene)-1,4,5-tri-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)myo-inositol 
• 139640-12-3 (3aR,4S,5S,6R,7S,7aS)-6-Benzyloxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole-4,5,7-triol 
• 104846-25-5 Phosphoric acid mono-((1R,2R,3S,4R,5R,6S)-2,3,6-tris-benzyloxy-4,5-bis-phosphonooxy-cyclohexyl) ester 
• 120065-88-5 Benzoic acid (1R,2S,3R,4R,5S,6S)-2,5-bis-benzyloxy-3,4,6-tris-(bis-benzyloxy-phosphoryloxy)-cyclohexyl ester 
• 143366-69-2 1-<3-Aminopropoxy(hydroxy)phosphinyl>-2,3,6-tri-O-benzoyl-D-myo-inositol 4,5-bisphosphate 
• 207128-85-6 4-O-benzyl-1,2-O-isopropylidene-myoinositol 3,5,6-tris(dibenzyl phosphate) 
• 220153-09-3 Phosphoric acid mono-((1R,2R,3S,4R,5R,6S)-3-benzyloxy-2,6-bis-benzyloxymethoxy-4,5-bis-phosphonooxy-cyclohexyl) ester 
• 342789-76-8 (-)-D-3-O-benzyl-2,6-O-bisbenzyloxymethyl-myo-inositol 1,4,5-tris(dibenzyl phosphate) 
• 864372-86-1 2-O-acetyl-3,6-di-O-benzyl-1,4,5-tris-O-(3-oxo-1,5-dihydro-3λ⁵-2,4,3-benzodioxaphosphepin-3-yl)-D-myo-inositol 
• 864372-85-0 2-O-acetyl-3,6-di-O-benzyl-D-myo-inositol 

Relevant articles and documents

Incorporation of a fluorous diazirine group into phosphatidylinositol 4,5-bisphosphate to illustrate its interaction with ADP-ribosylation factor 1

Phosphatidylinositides are one family of the most versatile signaling molecules in cells, yet how they interact with different proteins to regulate biological processes is not well understood. Towards a general strategy to identify phosphatidylinositide-protein interactions, a fluorous diazirine group has been incorporated into phosphatidylinositol 4,5-bisphosphate (PIP 2). The modified PIP2 was effectively cleaved by phospholipase C, one signaling protein that utilizes PIP2 as its endogenous substrate. Upon light illumination, the PIP2 probe effectively crosslinks with small GTPase ADP-ribosylation 1 to form a complex, suggesting that the probe might be suitable to identify PIP2- interacting proteins on the proteome level. The Royal Society of Chemistry 2012.

Synthesis of unsaturated phosphatidylinositol 4,5-bisphosphate and analogues

A new approach for the synthesis of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] is described, compatible with unsaturated fatty acid esters, as well as phosphorothioate and acetylenic analogues. This strategy depends on masking the ph

Divergent syntheses of all possible optically active regioisomers of myo-inositol tris- and tetrakisphosphates

Since the discovery of D-myo-inositol 1,4,5-trisphosphate, which plays a pivotal role as a second messenger in transmembrane signaling, the scope of the phosphoinositide-based signaling processes has been continually expanding. However, the clear understanding of the molecular signal transduction mechanisms including the functions of newly found IPn is still lacking. As a continuing effort to our previously reported syntheses of all possible 39 optically inactive regioisomers of myoinositol phosphates (IPn; n = 1-6), we synthesized all possible optically active regioisomers of myo-IP3 and myo-IP4 using chiral IBz3s and IBz2s, respectively. A series of procedures involving CRL-catalyzed enzymatic resolution of racemic 1,2:5,6-di-O-isopropylidene-myo-inositol and base-catalyzed benzoyl migration in tri- and dibenzoyl-isopropylidene-myo-inositol afforded eight enantiomeric pairs of IBz3 and six enantiomeric pairs of IBz2, respectively. Phosphorylation of these intermediates by the phosphitylation and oxidation procedure gave the target products.